Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Insider Eric Benevich Sells 19,818 Shares

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider Eric Benevich sold 19,818 shares of the stock in a transaction on Monday, April 15th. The shares were sold at an average price of $133.36, for a total value of $2,642,928.48. Following the sale, the insider now owns 40,778 shares in the company, valued at approximately $5,438,154.08. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Eric Benevich also recently made the following trade(s):

• On Thursday, March 14th, Eric Benevich sold 75,000 shares of Neurocrine Biosciences stock. The stock was sold at an average price of $139.38, for a total value of $10,453,500.00.

Neurocrine Biosciences Trading Up 0.2 %

NASDAQ:NBIX traded up $0.24 during mid-day trading on Wednesday, hitting $133.23. The company had a trading volume of 571,073 shares, compared to its average volume of 851,005. Neurocrine Biosciences, Inc. has a 1 year low of $89.04 and a 1 year high of $148.37. The firm has a market capitalization of $13.26 billion, a price-to-earnings ratio of 55.45 and a beta of 0.25. The business has a fifty day simple moving average of $136.25 and a 200-day simple moving average of $126.77.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings results on Wednesday, February 7th. The company reported $1.44 EPS for the quarter, topping analysts’ consensus estimates of $1.13 by $0.31. The business had revenue of $515.20 million during the quarter, compared to the consensus estimate of $518.52 million. Neurocrine Biosciences had a return on equity of 12.85% and a net margin of 13.23%. The company’s revenue for the quarter was up 25.0% compared to the same quarter last year. During the same period last year, the firm earned $0.88 earnings per share. As a group, research analysts anticipate that Neurocrine Biosciences, Inc. will post 4.84 earnings per share for the current year.

Wall Street Analysts Forecast Growth

NBIX has been the topic of several analyst reports. Citigroup decreased their price objective on Neurocrine Biosciences from $141.00 to $140.00 and set a “neutral” rating on the stock in a report on Thursday, February 8th. Wells Fargo & Company raised their price objective on Neurocrine Biosciences from $127.00 to $140.00 and gave the stock an “equal weight” rating in a report on Thursday, February 8th. Mizuho raised their price objective on Neurocrine Biosciences from $116.00 to $140.00 and gave the stock a “neutral” rating in a report on Thursday, February 8th. The Goldman Sachs Group raised their price objective on Neurocrine Biosciences from $134.00 to $153.00 and gave the stock a “buy” rating in a report on Thursday, January 25th. Finally, StockNews.com raised Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a research report on Thursday, February 8th. Six investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Neurocrine Biosciences has a consensus rating of “Moderate Buy” and a consensus target price of $139.67.

Hedge Funds Weigh In On Neurocrine Biosciences

Hedge funds have recently bought and sold shares of the company. FCF Advisors LLC acquired a new position in Neurocrine Biosciences in the fourth quarter valued at approximately $1,157,000. Redhawk Wealth Advisors Inc. bought a new stake in Neurocrine Biosciences during the fourth quarter worth approximately $1,245,000. Nordea Investment Management AB increased its holdings in shares of Neurocrine Biosciences by 205.7% in the third quarter. Nordea Investment Management AB now owns 28,591 shares of the company’s stock valued at $3,279,000 after buying an additional 19,238 shares in the last quarter. DekaBank Deutsche Girozentrale increased its holdings in shares of Neurocrine Biosciences by 28.3% in the fourth quarter. DekaBank Deutsche Girozentrale now owns 69,596 shares of the company’s stock valued at $9,138,000 after buying an additional 15,367 shares in the last quarter. Finally, Teza Capital Management LLC bought a new position in shares of Neurocrine Biosciences in the third quarter valued at $1,442,000. 92.59% of the stock is currently owned by institutional investors and hedge funds.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.